VHIO - Articles científics: Recent submissions
Now showing items 396-400 of 1250
-
A pragmatic guide for management of adverse events associated with lorlatinib
(Elsevier, 2024-03-14) -
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC
(Future Science Group, 2024-04)



